Sci Rep. 2018 Aug 28;8(1):12954. doi: 10.1038/s41598-018-31061-w.

Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer.

Hochmann S^1,2, Mittermeir M^1,2, Santic R³, Koszik F³, Griessner L³, Sonderegger AS^1,2, Hoffmann T³, Russe E⁴, Scheiblhofer S⁵, Weiss R⁵, Mandler M³, Schneeberger A³, Strunk D^6,7.

Abstract

Application of in vitro transcribed (IVT) messenger ribonucleic acid (mRNA) is an increasingly popular strategy to transiently produce proteins as therapeutics in a tissue or organ of choice. Here, we focused on the skin and aimed to test if whole human skin tissue explant technology can be used to evaluate the expression efficacy of different IVT Interferon alpha (IFN-α) mRNA constructs in situ, after biolistic delivery. Skin explants were viable and intact for at least five days based on histologic analysis and TUNEL staining. Using GFP reporter mRNA formulations, we found mostly epidermal expression after biolistic delivery. Two out of five sequence-optimized IFN-α mRNA variants resulted in significantly improved IFN-α protein expression in human skin compared to native IFN-α mRNA transfection. IFN-α secretion analysis of the surrounding culture media confirmed these results. We provide a proof-of-concept that IFN-α mRNA delivery into intact human full thickness skin explants can be utilized to test mRNA sequence modifications ex vivo. This approach could be used to develop novel mRNA-based treatments of common epidermal skin conditions including non-melanoma skin cancer, where IFN-α protein therapy has previously shown a strong therapeutic effect.